Schlusskurs
Andere Börsenplätze
|
||
- USD | - |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | - |
Chief Operating Officer | - | 01.06.18 | |
Steven Klayman
PRN | Corporate Officer/Principal | - | - |
Mostafa Abuzeid
PRN | Corporate Officer/Principal | - | - |
Hans Christinger
PRN | Corporate Officer/Principal | - | - |
Gilbert Jaoudé
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 3 204 401 | 2 483 540 ( 77,50 %) | 0 | 77,50 % |
Unternehmenskontakt
Innovus Pharmaceuticals, Inc.
373 Inverness Parkway Suite 206
80112, Englewood
+858-964-5123
http://www.innovuspharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+38.59% | 727 Mrd. | |
-7.89% | 347 Mrd. | |
+15.66% | 319 Mrd. | |
+0.24% | 274 Mrd. | |
+13.58% | 238 Mrd. | |
+6.95% | 204 Mrd. | |
-6.54% | 203 Mrd. | |
+4.23% | 161 Mrd. | |
-1.70% | 160 Mrd. |